Global Cell and Gene Therapy Drug Delivery Devices Market by Products
Global Cell and Gene Therapy Drug Delivery Devices Market by Commercialized Drugs
Global Cell and Gene Therapy Drug Delivery Devices Market by Region
Europe -
North America -
Asia Pacific -
Latin America -
Middle East & Africa -
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell and Gene Therapy Drug Delivery Devices Market Snapshot
Chapter 4. Global Cell and Gene Therapy Drug Delivery Devices Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Major Funding Investments in Cell and Gene Therapy Industry
4.8. COVID 19 Impact Analysis
Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2025 & 2035
5.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Products:
5.2.1. Subretinal Injection Cannula
5.2.2. Extension Tube
5.2.3. Intravenous Catheter
5.2.4. Sterile Insulin Syringe
5.2.5. Pre-Filled Syringe
5.2.6. Infusion Bags
Chapter 6. Cell and Gene Therapy Drug Delivery Devices Market Segmentation 2: By Commercialized Drugs Estimates & Trend Analysis
6.1. By Commercialized Drugs Analysis & Market Share, 2025 & 2035
6.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Commercialized Drugs:
6.2.1. Luxturna
6.2.2. Kymriah
6.2.3. Provenge
6.2.4. Zolgensma
6.2.5. Yescarta
6.2.6. Strimvelis
Chapter 7. Cell and Gene Therapy Drug Delivery Devices Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts By Products, 2022 - 2035
7.1.2. North America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts By Commercialized Drugs, 2022 - 2035
7.1.3. North America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by country, 2022 - 2035
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, 2022 - 2035
7.2.2. Europe Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, 2022 - 2035
7.2.3. Europe Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, 2022 - 2035
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, 2022 - 2035
7.3.2. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, 2022 - 2035
7.3.3. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, 2022 - 2035
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, (US$ Million) 2022 - 2035
7.4.2. Latin America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, (US$ Million) 2022 - 2035
7.4.3. Latin America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, (US$ Million) 2022 - 2035
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, (US$ Million) 2022 - 2035
7.5.2. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, (US$ Million) 2022 - 2035
7.5.3. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, (US$ Million) 2022 - 2035
7.5.4. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, (US$ Million) 2022 - 2035
7.5.4.1. South Africa
7.5.4.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Amgen Inc.
8.2.2. Bausch & Lomb Incorporated.
8.2.3. Becton, Dickinson and Company
8.2.4. Bluebird bio, Inc.
8.2.5. Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
8.2.6. Dendreon Pharmaceuticals LLC.
8.2.7. Helixmith Co., Ltd (ViroMed Co., Ltd)
8.2.8. Human Stem Cells Institute
8.2.9. Kite Pharma, Inc.
8.2.10. Kolon TissueGene, Inc.
8.2.11. Novartis AG
8.2.12. Orchard Therapeutics plc.
8.2.13. Pfizer, Inc.
8.2.14. Renova Therapeutics
8.2.15. Spark Therapeutics, Inc.
8.2.16. uniQure N.V.
8.2.17. Vericel Corporation
8.3. List of Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.